COMPANY

Cytokinetics

HQ: South San Francisco, CA source · cytokinetics.com ↗ · West Coast

FDA-approved therapeutic company Clinical Phase 3

86 open jobs · last seen Oct 23, 2026 · 52 sources

Location: South San Francisco, CA · source · Oct 15, 2026

Keywords: Heart Failure Heart Failure With Reduced Ejection Fraction Amyotrophic Lateral Sclerosis Symptomatic Obstructive Hypertrophic Cardiomyopathy Obstructive Hypertrophic Cardiomyopathy Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF) Pediatric Hypertrophic Cardiomyopathy Symptomatic Hypertrophic Cardiomyopathy (HCM) QT Intervals Changes QTc Intervals Changes Left Ventricular Systolic Dysfunction Chronic Heart Failure History of Chronic Heart Failure Left Ventricular Ejection Fraction Echocardiogram Chronic Heart Failure With Reduced Ejection Fraction Spinal Muscular Atrophy Non-Hodgkin's Lymphoma Hodgkin's Disease Myasthenia Gravis Intermittent Claudication Peripheral Artery Disease Breast Neoplasms Myocardial Ischemia Angina Pectoris malaria Reldesemtiv Omecamtiv Mecarbil Aficamten tirasemtiv SB-743921 CK-4021586

Since the raise (May 8, 2026): 86 of 86 open jobs were first seen after it.

86Open jobs $805.0MRaised (2 yrs)41Trials (company is sponsor)1FDA records (2 yrs)7NIH grants

Hiring

Title	Location (from posting)	Employer posted	First seen
Senior Scientist	South San Francisco, California	Oct 22, 2026	Oct 23, 2026
Associate Director, Business Insights & Analytics Data Scientist	Radnor, Pennsylvania	Oct 22, 2026	Oct 23, 2026
Senior Manager, CMC Analytical Chemistry	South San Francisco, California	Oct 22, 2026	Oct 23, 2026
Senior Manager, IT Technical Security	South San Francisco, California	Oct 22, 2026	Oct 23, 2026
Associate Director, Business Insights & Analytics	Radnor, Pennsylvania	Oct 22, 2026	Oct 23, 2026

See all 86 jobs

Trial and FDA signals

Drug approval + hiring FDA novel approval for MYQORZO (NDA 219083, Dec 19, 2025); 49 manufacturing/quality or commercial roles open. FDA NDA 219083 (Dec 19, 2025)
Evidence (1 event)
- Dec 19, 2025 · FDA NDA 219083
  openFDA drugsfda: application_number=NDA219083; sponsor_name='CYTOKINETICS'; submission_type=ORIG; submission_number=1; submission_status=AP; submission_status_date=20251219; submission_class_code=TYPE 1; brand_name=['MYQORZO']

Job counts as of Oct 18, 2026. All trial and FDA signals

Timeline

Oct 5, 2026 Board tracked Radar started tracking this company’s job board (86 open jobs at last check). source ↗
May 8, 2026 Raise Follow-on offering: $805M (total, as published), announced May 8, 2026. Source: company release on GlobeNewswire. source ↗
Dec 19, 2025 FDA FDA New drug/biologic (novel): MYQORZO (aficamten) — NDA219083, Dec 19, 2025. Applicant at approval: Cytokinetics, Incorporated. source ↗
Sep 16, 2025 Debt Debt: $650M (not counted as a raise), announced Sep 16, 2025. Source: SEC filing. source ↗
Feb 6, 2025 Trial start Phase 2: AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF source ↗
Dec 19, 2024 Trial start Phase 3: Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction source ↗
May 29, 2024 Trial start Phase 2/Phase 3: A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM). source ↗
Aug 31, 2023 Trial start Phase 3: A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) source ↗
Jun 20, 2023 Trial start 3: Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM source ↗
May 15, 2023 Trial start Phase 1: Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval source ↗
May 9, 2023 Trial start Phase 1: A Single and Multiple Ascending Dose Study of CK-4021586 in Healthy Adult Participants source ↗
Dec 6, 2022 Trial start Phase 1: A Single and Multiple Ascending Dose Study of CK-3828136 in Healthy Adult Participants source ↗
Aug 4, 2022 Trial start 3: A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031) source ↗
Feb 1, 2022 Trial start 3: Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM source ↗
Aug 16, 2021 Trial start Phase 3: A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS) source ↗
May 6, 2021 Trial start Phase 2/Phase 3: Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM source ↗
Dec 18, 2020 Trial start Phase 3: Omecamtiv Mecarbil Post-trial Access Study source ↗
Jan 10, 2020 Trial start Phase 2: Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Hypertrophic Cardiomyopathy source ↗
Nov 14, 2019 Trial start Phase 1: Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy Adults source ↗
Apr 9, 2019 Trial start Phase 3: Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure source ↗
Dec 4, 2018 Trial start Phase 1: A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subjects source ↗
Jul 24, 2017 Trial start Phase 2: A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS) source ↗
Jan 6, 2017 Trial start Phase 3: Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction source ↗
Oct 17, 2016 Trial start Phase 3: A Study for Patients Who Completed VITALITY-ALS (CY 4031) source ↗
Apr 14, 2016 Trial start Phase 2: Safety, PK, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced Ejection Fraction source ↗

Showing 25 of 45 dated events.

Upcoming milestones

2027-09 (ESTIMATED) · Phase 3 · Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction · NCT06736574
2028-03 (ESTIMATED) · Phase 2/Phase 3 · Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM · NCT04848506
2030-01 (ESTIMATED) · Phase 2/Phase 3 · A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM). · NCT06412666

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 86

Title	Location (from posting, not HQ)	Employer posted	First seen	Level
Senior Scientist	South San Francisco, California	Oct 22, 2026	Oct 23, 2026	Not stated
Associate Director, Business Insights & Analytics Data Scientist	Radnor, Pennsylvania	Oct 22, 2026	Oct 23, 2026	Not stated
Senior Manager, CMC Analytical Chemistry	South San Francisco, California	Oct 22, 2026	Oct 23, 2026	Not stated
Senior Manager, IT Technical Security	South San Francisco, California	Oct 22, 2026	Oct 23, 2026	Not stated
Associate Director, Business Insights & Analytics	Radnor, Pennsylvania	Oct 22, 2026	Oct 23, 2026	Not stated
Cardiovascular Account Specialist - U.S. Sales, San Antonio, TX	Remote	Oct 22, 2026	Oct 23, 2026	Not stated
Associate Director, Patient Support Services Operations	Radnor, Pennsylvania	Oct 20, 2026	Oct 21, 2026	Not stated
Senior Quality Assurance Specialist - Drug Substance	South San Francisco, California	Oct 19, 2026	Oct 5, 2026	Senior
Senior Quality Assurance Specialist - Drug Product	Radnor, Pennsylvania	Oct 19, 2026	Oct 5, 2026	Senior
Manager, Quality Systems - GxP Training (Contract)	South San Francisco, California	Oct 19, 2026	Oct 5, 2026	Mid
Director, Quality Systems	South San Francisco, California	Oct 19, 2026	Oct 5, 2026	Senior
Field Access Manager (FAM) - Southeast	Remote	Oct 19, 2026	Oct 5, 2026	Senior
Director, QA Operations	3 locations (listed on the posting)	Oct 19, 2026	Oct 5, 2026	Senior
Senior Scientist II, Statistical Genetics	South San Francisco, California	Oct 19, 2026	Oct 20, 2026	Not stated
Director, Clinical Quality Assurance	South San Francisco, California	Oct 16, 2026	Oct 5, 2026	Senior
Senior Director, Medical Safety & Pharmacovigilance	2 locations (listed on the posting)	Oct 16, 2026	Oct 5, 2026	Senior
Principal Scientist, Translational Biology	South San Francisco, California	Oct 16, 2026	Oct 16, 2026	Not stated
Order to Cash Manager, Europe (6 months contract position)	Ireland	Oct 13, 2026	Oct 5, 2026	Senior
Senior Director, Biostatistics	South San Francisco, California	Oct 13, 2026	Oct 14, 2026	Senior
Executive Director and Head of Alliance Management	South San Francisco, California	Oct 12, 2026	Oct 5, 2026	Executive
Director, Commercial Regulatory Europe	Zug, Switzerland	Oct 9, 2026	Oct 10, 2026	Senior
Director, Quality Operations, Supply Chain Oversight & EU Responsible Person	Ireland	Oct 8, 2026	Oct 5, 2026	Senior
Key Account Manager, Cardiovascular (Munich, Germany)	Remote - Germany	Oct 8, 2026	Oct 8, 2026	Mid
Medical Director, US Medical Affairs, HCM	2 locations (listed on the posting)	Oct 7, 2026	Oct 5, 2026	Senior
Senior Quality Assurance Specialist - Drug Product	Ireland	Oct 6, 2026	Oct 6, 2026	Senior
Senior Quality Assurance Specialist - Drug Substance	Ireland	Oct 6, 2026	Oct 6, 2026	Senior
Senior Pharmacovigilance Operations Manager	South San Francisco, California	Oct 5, 2026	Oct 5, 2026	Senior
Senior Legal Counsel, Europe	Ireland	Oct 2, 2026	Oct 5, 2026	Senior
Director, Corporate Securities & Governance Counsel	South San Francisco, California	Oct 2, 2026	Oct 5, 2026	Senior
Senior Director, Legal Counsel	South San Francisco, California	Oct 2, 2026	Oct 5, 2026	Senior
Cardiovascular Account Specialist - U.S. Sales, Pasadena, CA	Remote	Sep 30, 2026	Oct 5, 2026	Mid
Cardiovascular Account Specialist - U.S. Sales, Arlington, VA	2 locations (listed on the posting)	Sep 28, 2026	Oct 5, 2026	Mid
Director, HCP Personal Promotion Marketing	2 locations (listed on the posting)	Sep 23, 2026	Oct 5, 2026	Senior
Senior Manager, Healthcare Compliance	Radnor, Pennsylvania	Sep 23, 2026	Oct 5, 2026	Senior
Scientist II	South San Francisco, California	Sep 23, 2026	Oct 5, 2026	Mid
Senior Manager, Regulatory Affairs CMC	Radnor, Pennsylvania	Sep 23, 2026	Oct 5, 2026	Senior
Senior Manager, Regulatory Operations & Systems	South San Francisco, California	Sep 23, 2026	Oct 5, 2026	Senior
Scientist I	South San Francisco, California	Sep 23, 2026	Oct 5, 2026	Entry
Senior Manager, Regulatory Operations - Systems	Radnor, Pennsylvania	Sep 23, 2026	Oct 5, 2026	Senior
Director, US Regulatory Affairs, Advertising & Promotion	Radnor, Pennsylvania	Sep 23, 2026	Oct 5, 2026	Senior
Field Access Manager (FAM) - Southern California	Remote	Sep 23, 2026	Oct 5, 2026	Senior
Field Access Manager (FAM) - Rocky Mountain	Remote	Sep 23, 2026	Oct 5, 2026	Senior
Field Access Manager (FAM) - Mid South	Remote	Sep 23, 2026	Oct 5, 2026	Senior
Field Access Manager (FAM) - New York City	Remote	Sep 23, 2026	Oct 5, 2026	Senior
Field Access Manager (FAM) - Pacific Coast	Remote	Sep 23, 2026	Oct 5, 2026	Senior
Field Access Manager (FAM) - Gulf Coast	Remote	Sep 23, 2026	Oct 5, 2026	Senior
Field Access Manager (FAM) - Northeast	Remote	Sep 23, 2026	Oct 5, 2026	Senior
Field Access Manager (FAM) - Mid Atlantic	Remote	Sep 23, 2026	Oct 5, 2026	Senior
Field Access Manager (FAM) - Allegheny	Remote	Sep 23, 2026	Oct 5, 2026	Senior
Field Access Manager (FAM) - Southern Florida	Remote	Sep 23, 2026	Oct 5, 2026	Senior

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

All 86 jobs →

Funding

Raised: $805.0M · Debt: $650.0M. Last 2 years.

May 8, 2026 Follow-on offering: $805M (total, as published), announced May 8, 2026. Source: company release on GlobeNewswire. source ↗
Sep 16, 2025 Debt: $650M (not counted as a raise), announced Sep 16, 2025. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 41

Record	Title	Phase	Status	Start	Primary completion
NCT06736574	Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction	Phase 3	Recruiting	Dec 19, 2024	2027-09 (estimated)
NCT06081894	A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)	Phase 3	Active, not recruiting	Aug 31, 2023	Aug 31, 2026 (actual)
NCT06793371	AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF	Phase 2	Recruiting	Feb 6, 2025	2026-09 (estimated)
NCT06412666	A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).	Phase 2/Phase 3	Active, not recruiting	May 29, 2024	2030-01 (estimated)
NCT05767346	Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM	3	Completed	Jun 20, 2023	Feb 28, 2025 (actual)
NCT05186818	Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM	3	Completed	Feb 1, 2022	Nov 10, 2023 (actual)
NCT04219826	Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Hypertrophic Cardiomyopathy	Phase 2	Completed	Jan 10, 2020	Feb 28, 2023 (actual)
NCT04848506	Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM	Phase 2/Phase 3	Enrolling by invitation	May 6, 2021	2028-03 (estimated)
NCT05877053	A Single and Multiple Ascending Dose Study of CK-4021586 in Healthy Adult Participants	Phase 1	Completed	May 9, 2023	Nov 20, 2024 (actual)
NCT04175808	Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy Adults	Phase 1	Completed	Nov 14, 2019	Mar 4, 2020 (actual)
NCT03767855	A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subjects	Phase 1	Completed	Dec 4, 2018	Jan 3, 2020 (actual)
NCT04944784	A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)	Phase 3	Terminated	Aug 16, 2021	Jul 18, 2023 (actual)
NCT05662215	A Single and Multiple Ascending Dose Study of CK-3828136 in Healthy Adult Participants	Phase 1	Terminated	Dec 6, 2022	Aug 8, 2023 (actual)
NCT05442775	A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)	3	Terminated	Aug 4, 2022	Jun 7, 2023 (actual)
NCT05924815	Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval	Phase 1	Completed	May 15, 2023	Nov 14, 2023 (actual)
NCT03759392	Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure	Phase 3	Completed	Apr 9, 2019	Nov 8, 2021 (actual)
NCT02929329	Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction	Phase 3	Completed	Jan 6, 2017	Sep 14, 2020 (actual)
NCT01786512	COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure	Phase 2	Completed	Feb 26, 2013	Jul 22, 2015 (actual)
NCT01077167	Pharmacokinetic Study of Omecamtiv Mecarbil in Heart Failure Patients	Phase 2	Withdrawn	2010-07	2011-05 (actual)
NCT01737866	Pharmacokinetics Study of AMG 423 in Healthy Subjects and Subjects With Various Degrees of Renal Insufficiency	Phase 1	Completed	2012-11	2013-01 (actual)
NCT04464525	Omecamtiv Mecarbil Post-trial Access Study	Phase 3	Withdrawn	Dec 18, 2020	Nov 27, 2026 (estimated)
NCT02601001	Pharmacokinetics and Safety Study of Omecamtiv Mecarbil in Healthy Japanese Adults	Phase 1	Completed	Nov 13, 2015	Jan 6, 2016 (actual)
NCT01300013	Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure (ATOMIC-AHF)	Phase 2	Completed	2011-04	2013-04 (actual)
NCT02695420	Safety, PK, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced Ejection Fraction	Phase 2	Completed	Apr 14, 2016	Apr 6, 2017 (actual)
NCT02936635	A Study for Patients Who Completed VITALITY-ALS (CY 4031)	Phase 3	Completed	Oct 17, 2016	Oct 26, 2018 (actual)
NCT00624442	A Study of CK-1827452 Infusion in Stable Heart Failure	Phase 2	Completed	2007-04	2009-02 (actual)
NCT03160898	A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)	Phase 2	Completed	Jul 24, 2017	Mar 7, 2019 (actual)
NCT02496767	Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year	Phase 3	Completed	Sep 3, 2015	Mar 9, 2017 (actual)
NCT02644668	A Study of CK-2127107 in Patients With Spinal Muscular Atrophy	Phase 2	Completed	Jan 14, 2016	May 31, 2018 (actual)
NCT01709149	Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)	Phase 2	Completed	2012-10	2014-03 (actual)
NCT00748579	Phase II Study of the Effect of CK-1827452 Injection on Myocardial Efficiency	II	Terminated	2008-09	2008-11 (actual)
NCT00343564	A Study of SB-743921 in Non-Hodgkin Lymphoma and Hodgkin Lymphoma	Phase 1/Phase 2	Completed	2006-04	2010-07 (actual)
NCT01268280	Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis	Phase 2	Terminated	2010-12	2012-10 (actual)
NCT01131013	A Study of CK-2017357 in Patients With Peripheral Artery Disease and Symptomatic Claudication	Phase 2	Completed	2010-05	2011-03 (actual)
NCT01089010	A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)	Phase 2	Completed	2010-03	2010-11 (actual)
NCT01378676	A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)	Phase 2	Completed	2011-06	2012-03 (actual)
NCT00607841	A Study of Ispinesib in Metastatic Breast Cancer	Phase 1	Terminated	2007-12	2009-11 (actual)
NCT01486849	Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)	Phase 2	Completed	2011-11	2012-03 (actual)
NCT00682565	PK and Tolerability of IV and Oral CK-1827452 in Patients With Ischemic Cardiomyopathy and Angina	Phase 2	Completed	2008-04	2008-11 (actual)
NCT01380223	A Pharmacokinetic and Pharmacodynamic Study of Omecamtiv Mecarbil in Healthy Volunteers	Phase 1	Completed	2005-08	2006-04 (actual)
NCT00941681	Pharmacokinetics of Oral CK-1827452 in Patients With Stable Heart Failure	Phase 2	Completed	2009-04	2009-10 (actual)

FDA records (last 2 years)

Dec 19, 2025 FDA New drug/biologic (novel): MYQORZO (aficamten) — NDA219083, Dec 19, 2025. Applicant at approval: Cytokinetics, Incorporated. source ↗

NIH awards 7

Annual award amounts. Total $4.0M.

Sep 21, 2012 NIH award 3RC3NS070670-01S1 FY2012: $530,523 awarded for that fiscal year; activity RC3 (OTHER_NIH); PI MALIK, FADY; recipient as written: CYTOKINETICS, INC., SOUTH SAN FRANCISCO, CA. Pre-Clinical and Clinical Evalua source ↗
Jul 23, 2010 NIH award 1RC3NS070670-01 FY2010: $2,948,895 awarded for that fiscal year; activity RC3 (OTHER_NIH); PI MALIK, FADY; recipient as written: CYTOKINETICS, INC., SOUTH SAN FRANCISCO, CA. Pre-Clinical and Clinical Evalua source ↗
2003 NIH award 1R43AI055138-01 FY2003: $100,000 awarded for that fiscal year; activity R43 (SBIR); PI HEKMAT-NEJAD, MOHAMMAD; recipient as written: CYTOKINETICS, INC., SOUTH SAN FRANCISCO, CA. Mitotic Kinesins: Novel Targ source ↗
Sep 28, 2001 NIH award 1R43HL068349-01 FY2001: $99,900 awarded for that fiscal year; activity R43 (SBIR); PI HARTMAN, JAMES JOSEPH; recipient as written: CYTOKINETICS, INC., SOUTH SAN FRANCISCO, CA. A Novel Approach to Identify S source ↗
Mar 19, 2001 NIH award 1R43AI049598-01 FY2001: $100,000 awarded for that fiscal year; activity R43 (SBIR); PI NISLOW, COREY EVAN; recipient as written: CYTOKINETICS, INC., SOUTH SAN FRANCISCO, CA. Actin-binding proteins as novel source ↗
Feb 12, 2001 NIH award 1R43AI048969-01 FY2001: $100,000 awarded for that fiscal year; activity R43 (SBIR); PI NISLOW, COREY EVAN; recipient as written: CYTOKINETICS, INC., SOUTH SAN FRANCISCO, CA. A NOVEL TARGET FOR THE DEVELOPME source ↗
Jan 7, 2001 NIH award 1R43HL066647-01 FY2001: $99,900 awarded for that fiscal year; activity R43 (SBIR); PI MALIK, FADY; recipient as written: CYTOKINETICS, INC., SOUTH SAN FRANCISCO, CA. VALIDATION OF A NOVEL SARCOMERIC HIGH TH source ↗

Connect

See your connections at Cytokinetics on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-12